isocoumarins has been researched along with isocoumarin nm-3 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agata, N; Hirano, S; Ishizuka, M; Isshiki, K; Kumagai, H; Maeda, K; Nakashima, T; Takeuchi, T; Yoshioka, T | 1 |
| Beckett, MA; Gupta, VK; Hari, DM; Hellman, S; Jaskowiak, NT; Kalluri, R; Koons, AM; Kufe, DW; Mauceri, HJ; Posner, MC; Reimer, C; Salloum, RM; Seetharam, S; Weichselbaum, RR | 1 |
| Hirano, SI; Ishizuka, M; Isshiki, K; Kuboki, H; Kumagai, H; Matsumoto, N; Nakashima, T; Takeuchi, T; Yoshioka, T | 1 |
| Agata, N; Bamberg, M; Dickerson, WM; Fram, R; Kalluri, R; Kamphaus, GD; Kharbanda, S; Kufe, D; Milhollen, M; Reimer, CL; Rook, SL; Tammam, JG | 1 |
| Kharbanda, S; Kufe, D; Ohno, T; Weichselbaum, R; Yin, L | 1 |
| Isshiki, K; Konuki, K; Kuroda, A; Nagai, H; Nakamura, H; Nakashima, T; Takeuchi, T; Tsuchida, T; Yoshida, M | 1 |
| Bauta, WE; Burke, BD; Cantrell, WR; Lovett, DP | 1 |
| Chen, GQ; Chen, JL; Shen, B; Yu, HF; Yu, XH; Zhu, JS; Zhu, ZM | 1 |
| Agata, N; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H | 1 |
| Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S | 1 |
| Agata, N; Hirokoshi, K; Ichinose, K; Kinomura, M; Kitayama, H; Maeshima, Y; Makino, H; Sugiyama, H; Takazawa, Y; Yamamoto, Y; Yamasaki, Y | 1 |
| Agata, N; Avigan, D; Kawano, T; Kharbanda, S; Kufe, D | 1 |
| Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM | 1 |
| Chen, JL; Da, W; Song, MQ; Wang, L; Zhang, WP; Zhu, JS; Zhu, L | 1 |
| Chen, GQ; Li, Q; Song, MQ; Sun, Q; Zhang, Q; Zhu, JS | 1 |
15 other study(ies) available for isocoumarins and isocoumarin nm-3
| Article | Year |
|---|---|
Inhibition of angiogenesis by a new isocoumarin, NM-3.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Coumarins; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Female; Isocoumarins; Mice; Mice, Inbred ICR; Neovascularization, Pathologic; Sarcoma 180; Tumor Cells, Cultured | 1999 |
NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.
Topics: Adenocarcinoma; Animals; Carcinoma, Lewis Lung; Cell Movement; Cells, Cultured; Collagen; Coumarins; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Combinations; Endothelium, Vascular; Esophageal Neoplasms; Female; Humans; Isocoumarins; Laminin; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms; Proteoglycans; Radiation, Ionizing; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2000 |
Synthesis and biological evaluation of cytogenin derivatives.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Arthritis; Coumarins; Drug Stability; In Vitro Techniques; Isocoumarins; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred DBA; Mice, Inbred ICR; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2001 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Coumarins; Cyclophosphamide; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Growth Inhibitors; Humans; Isocoumarins; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2002 |
The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Coumarins; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Female; Humans; Immunoblotting; Isocoumarins; Necrosis; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Convenient total synthesis of NM-3, an antiangiogenesis agent, and its optical resolution.
Topics: Angiogenesis Inhibitors; Coumarins; Isocoumarins; Molecular Conformation | 2003 |
Formal synthesis of angiogenesis inhibitor NM-3.
Topics: Angiogenesis Inhibitors; Coumarins; Indicators and Reagents; Isocoumarins; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Conformation | 2003 |
Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Coumarins; Drug Synergism; Female; Humans; In Vitro Techniques; Isocoumarins; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2003 |
2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Coumarins; Cytochromes c; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Isocoumarins; Mitochondria; Mitochondrial Proteins; Multiple Myeloma; Reactive Oxygen Species | 2004 |
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Screening Assays, Antitumor; Humans; Isocoumarins; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Taxoids | 2005 |
2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
Topics: Angiogenesis Inhibitors; Animals; Chemokine CCL2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Heart; Insulin; Interleukin-6; Isocoumarins; Kidney; Liver; Mice; Obesity; Organ Size; Placebos; Polymerase Chain Reaction; Transforming Growth Factor beta | 2006 |
A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells.
Topics: Antimitotic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Isocoumarins; Microtubules; Mitosis; Multiple Myeloma | 2007 |
Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Humans; Isocoumarins; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Stomach Neoplasms; Transplantation, Heterologous | 2007 |
Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells.
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Isocoumarins; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Quinolizines; RNA, Messenger; Stomach Neoplasms; Survivin; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2007 |
Molecular mechanisms of paclitaxel and NM-3 on human gastric cancer in a severe combined immune deficiency mice orthotopic implantation model.
Topics: Adenocarcinoma; Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Isocoumarins; Male; Mice; Mice, Nude; Mice, SCID; Paclitaxel; Stomach Neoplasms; Viral Core Proteins; Xenograft Model Antitumor Assays | 2007 |